Abstract
China has a large and fast-growing pharmaceuticals industry. The estimated
value of the domestic industry in China, at the end of 2005, will be in the
region of RMB288.74bn (US$34.89bn), and will have grown by over 140% since
1998.
For the domestic industry in China, the problem is that, although it is one of
the world's largest bulk manufacturers of raw drugs ingredients, it has yet to
develop a real capability to develop its own proprietary drugs. This means
that 99% of the over-the-counter drugs sold in pharmacies in China were
developed by foreign companies. This means that China continues to pay a
royalty to these developers, for drugs it could easily be developing for
itself.
Given the huge size of the domestic market, both for OTC and prescription
drugs, the value of the royalties paid must be huge - which is why foreign
drugs makers are so keen to corner the market for themselves. However, the
Chinese manufacturers are at last beginning to work together to develop their
own patent drugs, in order to begin reaping real profits.
This report, as well as all the usual market size, share, breakdown and
forecast data, includes over 100 company profiles!
REPORT COVERAGE
This report covers the market for over-the-counter (OTC) pharmaceuticals in
the People's Republic of China. The report covers the following sectors:
- Analgesics
- Cough, cold and allergy (hay-fever) remedies
- Digestive remedies
- Medicated skincare
- Vitamins and dietary supplements
- Other OTC healthcare
| 
View Cart
